CAR-T Meeting 2022 | CAR-T therapy in second-line for NHL: ZUMA-7, TRANSFORM & BELINDA

At the last ASH meeting, as I have mentioned, we were able to see the results of three different Phase III prospective clinical trials. The design is not exactly the same in the three of them.
So ZUMA-7 for axi-cel, BELINDA for tisa-cel, and then TRANSFORM for liso-cel. But in summary, these three prospective clinical trials compared face-to-face in patients with primary refractory disease or in patients with early relapse, that in principle were transplant-eligible, the standard of care, so chemoimmunotherapy plus consolidation with autologous stem cell transplantation versus the three different CAR-T products. Two of these trials, ZUMA-7 and TRANSFORM were positive. So basically both of them demonstrated that the event-free survival for those patients that were treated with the CAR-T constructs was significantly better than the standard of care. And the medium follow-up was longer for the ZUMA-7. If we talk about overall survival, there were no significant differences in terms of overall survival between both arms, but still the follow-up is quite short. And probably we are seeing the beneficial impact of using cellular therapy as a third-line treatment. The safety profile was also quite favorable to the ‘experimental arm, and also the quality of life and patient-reported outcome measures.
So probably just because of this data coming from these two prospective clinical trials, maybe in the near future, the standard of care for patients with diffuse large B-cell lymphoma, primary refractory, or with early relapse will change both in the U.S and in Europe.